The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

Yiming Yang; Andrew J Sanders; Q Ping Dou; David G Jiang; Amber Xinyu Li; Wen G Jiang

doi:10.3390/cancers13205187

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

Cancers (Basel). 2021 Oct 15;13(20):5187. doi: 10.3390/cancers13205187.

Authors

Yiming Yang¹, Andrew J Sanders¹, Q Ping Dou^{1

2}, David G Jiang^{1

3}, Amber Xinyu Li¹, Wen G Jiang¹

Affiliations

¹ School of Medicine, Cardiff University, Henry Wellcome Building, Cardiff CF14 4XN, UK.
² Departments of Oncology, Pharmacology and Pathology School of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201-2013, USA.
³ Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust, Aylesbury HP21 8AL, UK.

Abstract

Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a cell adhesion protein that is found in multiple cell types. ALCAM has multiple and diverse roles in various physiological and pathological conditions, including inflammation and cancer. There has been compelling evidence of ALCAM's prognostic value in solid cancers, indicating that it is a potential therapeutic target. The present article overviews the recent findings and progress in ALCAM and its involvement in cancer, with a primary focus on its clinical connections in cancer and therapeutic values.

Keywords: ALCAM; CD166; activated leukocyte cell adhesion molecule; cancer; prognosis; survival; therapeutic targets.

Publication types

Review